OBJECTIVE: A hallmark of rheumatoid arthritis (RA) is the production of autoantibodies, including anti-citrullinated protein antibodies (ACPAs). Nevertheless, the specific targets of these autoantibodies remain incompletely defined. During an immune response, B cells specific for the inciting antigen(s) are activated and differentiate into plasmablasts, which are released into the blood. We undertook this study to sequence the plasmablast antibody repertoire to define the targets of the active immune response in RA. METHODS: We developed a novel DNA barcoding method to sequence the cognate heavy- and light-chain pairs of antibodies expressed by individual blood plasmablasts in RA. The method uses a universal 5' adapter that enables full-length sequencing of the antibodies' variable regions and recombinant expression of the paired antibody chains. The sequence data sets were bioinformatically analyzed to generate phylogenetic trees that identify clonal families of antibodies sharing heavy- and light-chain VJ sequences. Representative antibodies were expressed, and their binding properties were characterized using anti-cyclic citrullinated peptide 2 (anti-CCP-2) enzyme-linked immunosorbent assay (ELISA) and antigen microarrays. RESULTS: We used our sequencing method to generate phylogenetic trees representing the antibody repertoires of peripheral blood plasmablasts from 4 individuals with anti-CCP+ RA, and recombinantly expressed 14 antibodies that were either "singleton" antibodies or representative of clonal antibody families. Anti-CCP-2 ELISA identified 4 ACPAs, and antigen microarray analysis identified ACPAs that differentially targeted epitopes on α-enolase, citrullinated fibrinogen, and citrullinated histone H2B. CONCLUSION: Our data provide evidence that autoantibodies targeting α-enolase, citrullinated fibrinogen, and citrullinated histone H2B are produced by the ongoing activated B cell response in, and thus may contribute to the pathogenesis of, RA.
OBJECTIVE: A hallmark of rheumatoid arthritis (RA) is the production of autoantibodies, including anti-citrullinated protein antibodies (ACPAs). Nevertheless, the specific targets of these autoantibodies remain incompletely defined. During an immune response, B cells specific for the inciting antigen(s) are activated and differentiate into plasmablasts, which are released into the blood. We undertook this study to sequence the plasmablast antibody repertoire to define the targets of the active immune response in RA. METHODS: We developed a novel DNA barcoding method to sequence the cognate heavy- and light-chain pairs of antibodies expressed by individual blood plasmablasts in RA. The method uses a universal 5' adapter that enables full-length sequencing of the antibodies' variable regions and recombinant expression of the paired antibody chains. The sequence data sets were bioinformatically analyzed to generate phylogenetic trees that identify clonal families of antibodies sharing heavy- and light-chain VJ sequences. Representative antibodies were expressed, and their binding properties were characterized using anti-cyclic citrullinated peptide 2 (anti-CCP-2) enzyme-linked immunosorbent assay (ELISA) and antigen microarrays. RESULTS: We used our sequencing method to generate phylogenetic trees representing the antibody repertoires of peripheral blood plasmablasts from 4 individuals with anti-CCP+ RA, and recombinantly expressed 14 antibodies that were either "singleton" antibodies or representative of clonal antibody families. Anti-CCP-2 ELISA identified 4 ACPAs, and antigen microarray analysis identified ACPAs that differentially targeted epitopes on α-enolase, citrullinated fibrinogen, and citrullinated histone H2B. CONCLUSION: Our data provide evidence that autoantibodies targeting α-enolase, citrullinated fibrinogen, and citrullinated histone H2B are produced by the ongoing activated B cell response in, and thus may contribute to the pathogenesis of, RA.
Authors: Andreas Radbruch; Gwendolin Muehlinghaus; Elke O Luger; Ayako Inamine; Kenneth G C Smith; Thomas Dörner; Falk Hiepe Journal: Nat Rev Immunol Date: 2006-09-15 Impact factor: 53.106
Authors: Shuji Sato; Sean A Beausoleil; Lana Popova; Jason G Beaudet; Ravi K Ramenani; Xiaowu Zhang; James S Wieler; Sandra M Schieferl; Wan Cheung Cheung; Roberto D Polakiewicz Journal: Nat Biotechnol Date: 2012-11 Impact factor: 54.908
Authors: G A Schellekens; B A de Jong; F H van den Hoogen; L B van de Putte; W J van Venrooij Journal: J Clin Invest Date: 1998-01-01 Impact factor: 14.808
Authors: Kristine A Kuhn; Liudmila Kulik; Beren Tomooka; Kristin J Braschler; William P Arend; William H Robinson; V Michael Holers Journal: J Clin Invest Date: 2006-04 Impact factor: 14.808
Authors: Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig Journal: Nature Date: 2009-03-15 Impact factor: 49.962
Authors: Daniel R Lu; Andrew N McDavid; Sarah Kongpachith; Nithya Lingampalli; Jacob Glanville; Chia-Hsin Ju; Raphael Gottardo; William H Robinson Journal: Arthritis Rheumatol Date: 2018-09-24 Impact factor: 10.995
Authors: Jennifer D Kinslow; Lisa K Blum; Kevin D Deane; M Kristen Demoruelle; Yuko Okamoto; Mark C Parish; Sarah Kongpachith; Lauren J Lahey; Jill M Norris; William H Robinson; V Michael Holers Journal: Arthritis Rheumatol Date: 2016-10 Impact factor: 10.995
Authors: Jameson T Crowley; Klemen Strle; Elise E Drouin; Annalisa Pianta; Sheila L Arvikar; Qi Wang; Catherine E Costello; Allen C Steere Journal: J Autoimmun Date: 2016-02-26 Impact factor: 7.094
Authors: Song Li; Yangsheng Yu; Yinshi Yue; Hongyan Liao; Wanqin Xie; Jessica Thai; Ted R Mikuls; Geoffrey M Thiele; Michael J Duryee; Harlan Sayles; Jeffrey B Payne; Lynell W Klassen; James R O'Dell; Zhixin Zhang; Kaihong Su Journal: Arthritis Rheumatol Date: 2016-03 Impact factor: 10.995
Authors: M A Turchaninova; A Davydov; O V Britanova; M Shugay; V Bikos; E S Egorov; V I Kirgizova; E M Merzlyak; D B Staroverov; D A Bolotin; I Z Mamedov; M Izraelson; M D Logacheva; O Kladova; K Plevova; S Pospisilova; D M Chudakov Journal: Nat Protoc Date: 2016-08-04 Impact factor: 13.491
Authors: Lisa K Blum; Richard R L Cao; Andrew J Sweatt; Matthew Bill; Lauren J Lahey; Andrew C Hsi; Casey S Lee; Sarah Kongpachith; Chia-Hsin Ju; Rong Mao; Heidi H Wong; Mark R Nicolls; Roham T Zamanian; William H Robinson Journal: Eur J Immunol Date: 2018-02-22 Impact factor: 5.532
Authors: Abdulmohammad Pezeshki; Inna G Ovsyannikova; Brett A McKinney; Gregory A Poland; Richard B Kennedy Journal: Expert Rev Vaccines Date: 2019-02-11 Impact factor: 5.217